Predictive Factors of the Use of Rituximab and Belimumab in Spanish Lupus Patients
<i>Objectives</i>: To analyze the characteristics and the predictive factors of the use of rituximab and belimumab in daily practice in patients from the inception cohort Registro Español de Lupus (RELES). <i>Material and methods</i>: The study included 518 patients. We consi...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-07-01
|
| Series: | Medicina |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1648-9144/59/8/1362 |
| _version_ | 1827729264746692608 |
|---|---|
| author | O. Capdevila F. Mitjavila G. Espinosa L. Caminal-Montero A. Marín-Ballvè R. González León A. Castro J. Canora B. Pinilla E. Fonseca G. Ruiz-Irastorza |
| author_facet | O. Capdevila F. Mitjavila G. Espinosa L. Caminal-Montero A. Marín-Ballvè R. González León A. Castro J. Canora B. Pinilla E. Fonseca G. Ruiz-Irastorza |
| author_sort | O. Capdevila |
| collection | DOAJ |
| description | <i>Objectives</i>: To analyze the characteristics and the predictive factors of the use of rituximab and belimumab in daily practice in patients from the inception cohort Registro Español de Lupus (RELES). <i>Material and methods</i>: The study included 518 patients. We considered patients treated with biologics who received at least one dose of rituximab or belimumab, and possible indications of those manifestations registered at the same time or in the previous 2 months of the start of the therapy. <i>Results</i>: In our cohort, 37 (7%) patients received at least one biological treatment. Rituximab was prescribed in 26 patients and belimumab in 11. Rituximab was mainly prescribed for hemolytic anemia or thrombocytopenia (11 patients, 42%), lupus nephritis and neuropsychiatric lupus (5 patients each, 19%). Belimumab was mostly used for arthritis (8 patients, 73%). In the univariate analysis, the predictive factors at diagnosis for the use of biologic therapy were younger age (<i>p</i> = 0.022), a higher SLEDAI (<i>p</i> = 0.001) and the presence of psychosis (<i>p</i> = 0.011), organic mental syndrome (SOCA) (<i>p</i> = 0.006), hemolytic anemia (<i>p</i> = 0.001), or thrombocytopenia (<i>p</i> = 0.01). In the multivariant model, only younger age, psychosis, and hemolytic anemia were independent predictors of the use of biologics. <i>Conclusions</i>: Rituximab is usually given to patients with hematological, neuropsychiatric and renal involvement and belimumab for arthritis. Psychosis, hemolytic anemia and age at the diagnosis of lupus were independent predictive factors of the use of biological agents. Their global effects are beneficial, with a significant reduction in SLE activity and a low rate of side effects. |
| first_indexed | 2024-03-10T23:45:32Z |
| format | Article |
| id | doaj.art-54a3da409cc642e79752e077e723086a |
| institution | Directory Open Access Journal |
| issn | 1010-660X 1648-9144 |
| language | English |
| last_indexed | 2024-03-10T23:45:32Z |
| publishDate | 2023-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Medicina |
| spelling | doaj.art-54a3da409cc642e79752e077e723086a2023-11-19T02:05:00ZengMDPI AGMedicina1010-660X1648-91442023-07-01598136210.3390/medicina59081362Predictive Factors of the Use of Rituximab and Belimumab in Spanish Lupus PatientsO. Capdevila0F. Mitjavila1G. Espinosa2L. Caminal-Montero3A. Marín-Ballvè4R. González León5A. Castro6J. Canora7B. Pinilla8E. Fonseca9G. Ruiz-Irastorza10Autoimmune Diseases Unit, Department of Internal Medicine, Hospital Universitari de Bellvitge, L’Hospitalet de Llobregat, 08907 Barcelona, SpainAutoimmune Diseases Unit, Department of Internal Medicine, Hospital Universitari de Bellvitge, L’Hospitalet de Llobregat, 08907 Barcelona, SpainDepartment of Autoimmune Diseases, Hospital Clinic, 08036 Barcelona, SpainGroup of Basic and Translational Research in Inflammatory Diseases, Departament of Internal Medicine, Hospital Universitario Central de Asturias, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), 33011 Oviedo, SpainDepartment of Internal Medicine, Hospital Clínico Universitario Lozano Blesa, 50009 Zaragoza, SpainDepartment of Internal Medicine, Hospital Universitario Virgen del Rocío, 41013 Seville, SpainDepartment of Internal Medicine, Hospital Universitari Sant Joan de Reus, 43204 Reus, SpainDepartment of Internal Medicine, Hospital Universitario de Fuenlabrada, 28942 Madrid, SpainDepartment of Internal Medicine, Hospital General Universitario Gregorio Marañón, 28007 Madrid, SpainDepartment of Internal Medicine, Hospital de Cabueñes, 33394 Gijón, SpainAutoimmune Diseases Research Unit, Department of Internal Medicine, BioCruces Bizkaia Health Research Institute, Hospital Universitario Cruces, UPV/EHU, 48903 Barakaldo, Spain<i>Objectives</i>: To analyze the characteristics and the predictive factors of the use of rituximab and belimumab in daily practice in patients from the inception cohort Registro Español de Lupus (RELES). <i>Material and methods</i>: The study included 518 patients. We considered patients treated with biologics who received at least one dose of rituximab or belimumab, and possible indications of those manifestations registered at the same time or in the previous 2 months of the start of the therapy. <i>Results</i>: In our cohort, 37 (7%) patients received at least one biological treatment. Rituximab was prescribed in 26 patients and belimumab in 11. Rituximab was mainly prescribed for hemolytic anemia or thrombocytopenia (11 patients, 42%), lupus nephritis and neuropsychiatric lupus (5 patients each, 19%). Belimumab was mostly used for arthritis (8 patients, 73%). In the univariate analysis, the predictive factors at diagnosis for the use of biologic therapy were younger age (<i>p</i> = 0.022), a higher SLEDAI (<i>p</i> = 0.001) and the presence of psychosis (<i>p</i> = 0.011), organic mental syndrome (SOCA) (<i>p</i> = 0.006), hemolytic anemia (<i>p</i> = 0.001), or thrombocytopenia (<i>p</i> = 0.01). In the multivariant model, only younger age, psychosis, and hemolytic anemia were independent predictors of the use of biologics. <i>Conclusions</i>: Rituximab is usually given to patients with hematological, neuropsychiatric and renal involvement and belimumab for arthritis. Psychosis, hemolytic anemia and age at the diagnosis of lupus were independent predictive factors of the use of biological agents. Their global effects are beneficial, with a significant reduction in SLE activity and a low rate of side effects.https://www.mdpi.com/1648-9144/59/8/1362systemic lupus erythematosusbelimumabrituximab |
| spellingShingle | O. Capdevila F. Mitjavila G. Espinosa L. Caminal-Montero A. Marín-Ballvè R. González León A. Castro J. Canora B. Pinilla E. Fonseca G. Ruiz-Irastorza Predictive Factors of the Use of Rituximab and Belimumab in Spanish Lupus Patients Medicina systemic lupus erythematosus belimumab rituximab |
| title | Predictive Factors of the Use of Rituximab and Belimumab in Spanish Lupus Patients |
| title_full | Predictive Factors of the Use of Rituximab and Belimumab in Spanish Lupus Patients |
| title_fullStr | Predictive Factors of the Use of Rituximab and Belimumab in Spanish Lupus Patients |
| title_full_unstemmed | Predictive Factors of the Use of Rituximab and Belimumab in Spanish Lupus Patients |
| title_short | Predictive Factors of the Use of Rituximab and Belimumab in Spanish Lupus Patients |
| title_sort | predictive factors of the use of rituximab and belimumab in spanish lupus patients |
| topic | systemic lupus erythematosus belimumab rituximab |
| url | https://www.mdpi.com/1648-9144/59/8/1362 |
| work_keys_str_mv | AT ocapdevila predictivefactorsoftheuseofrituximabandbelimumabinspanishlupuspatients AT fmitjavila predictivefactorsoftheuseofrituximabandbelimumabinspanishlupuspatients AT gespinosa predictivefactorsoftheuseofrituximabandbelimumabinspanishlupuspatients AT lcaminalmontero predictivefactorsoftheuseofrituximabandbelimumabinspanishlupuspatients AT amarinballve predictivefactorsoftheuseofrituximabandbelimumabinspanishlupuspatients AT rgonzalezleon predictivefactorsoftheuseofrituximabandbelimumabinspanishlupuspatients AT acastro predictivefactorsoftheuseofrituximabandbelimumabinspanishlupuspatients AT jcanora predictivefactorsoftheuseofrituximabandbelimumabinspanishlupuspatients AT bpinilla predictivefactorsoftheuseofrituximabandbelimumabinspanishlupuspatients AT efonseca predictivefactorsoftheuseofrituximabandbelimumabinspanishlupuspatients AT gruizirastorza predictivefactorsoftheuseofrituximabandbelimumabinspanishlupuspatients |